Meet Senzime at Arab Health in Dubai, 29th January – 1st February

News; Uppsala, January 8, 2018.

Meet Senzime at WSM in London, 10-12 January

NEWS; Uppsala, January 5, 2018. For over 30 years the Winter Scientific Meeting (WSM) in London has been a great way for anaesthetists to develop their specialty knowledge and network with the wider anaesthesia community over three days. http://www.wsmlondon.org/

Press release; Senzime receives CE mark approval for the OnZurf Probe

Uppsala, December 18, 2017. Senzime AB (publ) announces that the company has received CE mark approval for the OnZurf Probe, which means that the product now is approved for sale on the European market.

Press release; Senzime receives CE mark approval for the TetraGraph

Uppsala, December 12, 2017.  Senzime AB (publ) announced today that it has received CE mark approval to enable the commercialization of the TetraGraph Neuromuscular Monitoring System. 

NEWS; Consensus Statement on Perioperative Use of Neuromuscular Monitoring

Uppsala, December 11, 2017.  A panel of clinician scientists with expertise in neuromuscular blockade (NMB) monitoring was convened with a charge to prepare a consensus statement on indications for, and proper use of, such monitors. This statement was published online at www.anesthesia-analgesia.org on November 30, 2017 (2018 in press), Copyright 2017 International Anesthesia Research Society.

Senzime’s Interim report January – September 2017

Uppsala, November 28, 2017. Senzime AB’s (publ) Interim report for January – September 2017 is now available on the company’s webbsite www.senzime.com.

Meet Senzime at Medica Trade Fair in Düsseldorf, 13-16 November

Uppsala, November 8, 2017. Medica Trade Fair in Düsseldorf is the world's leading trade fair for the medical industry. The fair consists of 17 halls where exhibitors from all over the world will present their products. Welcome to meet Senzime at Medica to learn more about our patient monitoring products OnZurf Probe, CliniSenz Analyzer and TetraGraph.

Senzime reports from the American Society of Anesthesiologists (ASA)

NEWS Uppsala, 26 October 2017. Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in Boston, USA. 

Comparative Investigation of TetraGraph and TOF-Watch SX

Press release Uppsala, 23 October 2017. Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TetraGraph and TOF-Watch SX. 

NEWS: Senzime reports from the Innovation Pavilion at The MedTech Conference

Uppsala, September 29, 2017. Senzime AB (publ) has been presenting the TetraGraph @ the Innovation Pavilion during The MedTech Conference in San José, California September 25-27. 

Senzime submits 510 (k) application to the FDA

Uppsala, September 25, 2017. Senzime AB (publ) announced today that the company has submitted a 510 (k) application to the US Food and Drug Administration (FDA) for approval of the TetraGraph in the United States. 

Senzime signs distribution agreement for the Swiss market

Uppsala, September 18, 2017. Senzime AB (publ) today announced an exclusive distribution agreement with Leuag AG regarding the Swiss market.

RESOLUTIONS AT SENZIME AB’S (PUBL) EXTRAORDINARY GENERAL MEETING

Senzime AB (publ) (the “Company”) held its Extraordinary General Meeting on September 15, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Notice of Extraordinary General Meeting of Senzime for the introduction of an employee stock option program

Uppsala, August 31, 2017. Senzime AB (publ) calls for an Extraordinary General Meeting for the introduction of an employee stock option program. The Board proposes that the General Meeting approve resolutions to issue no more than 1,300,000 warrants and to introduce an employee stock option plan. 

Senzime’s Interim report January – June 2017

Uppsala, August 31, 2017. Senzime AB’s (publ) Interim report for January – June 2017 is now available on the company’s webbsite www.senzime.com.

Senzime at the Innovation Pavilion

Uppsala, August 9, 2017. Senzime AB (publ) has been selected to exhibit at the Innovation Pavilion at The MedTech Conference in San José, California September 25-27. Ten innovative companies has been given this opportunity by AdvaMed.

Senzime obtains US patent

Uppsala, August 9, 2017. Senzime AB (publ) is awarded a U.S. patent for its TetraSens disposable electrodes. With its unique design, the TetraSens enables fast application and effective function. The electrodes are used in conjunction with Senzime's neuromuscular monitoring system, the TetraGraph, which contributes to effective, continuous monitoring of patients undergoing anesthesia and surgical muscle relaxation. The TetraGraph, via the interfaced TetraSens electrodes, makes it possible to easily and objectively determine the optimal dose of neuromuscular blocking drugs administered during the procedure, and to establish the appropriate time when it is safe to wake the patient after surgery and allow spontaneous breathing without the help of a ventilator. 

TetraGraph clinical use and comparison presented in ASA abstract

Uppsala, 21 June 2017. Senzime AB (publ) in partnership with Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TOF-Watch SX and the TetraGraph. 

Senzime receives ISO 13485 certification

Uppsala, June 12, 2017. Senzime AB (publ) has received ISO 13485 certification, which is an important milestone in the CE labeling process for the company's first monitoring products.

Interesting days at the Euroanesthesia 2017 meeting

Uppsala, June 8, 2017. As previously announced, Senzime AB (publ) participated at the Euroanesthesia (ESA) 2017 meeting in Geneva Switzerland June 3-5. ESA is the leading European Organisation for Anaesthesia, Critical Care, Pain and Perioperative Medicine. 

Senzime initiates clinical study with CliniSenz System

Uppsala, May 31, 2017. Senzime AB (publ) initiates a clinical trial with CliniSenz for monitoring of tissue lactate levels after surgery in patients with esophageal cancer, a disease that affects approximately 500,000 patients worldwide annually. The current treatment is mostly surgical with risk of multiple operations and increased mortality. With CliniSenz System, it is possible to monitor the healing process after surgery and detect complications at an early stage. The study has been approved by the Ethics Committee and is expected to start in the beginning of June 2017.

Meet Senzime at Euroanesthesia 2017

Uppsala, May 24, 2017.  Senzime AB (publ) will be participating at Euroanaesthesia 2017 in Geneva, Switzerland June 3-5, 2017. 

Senzime is granted additional patent for OnZurf Probe

Uppsala, 24 May 2017. Senzime AB’s (publ) application regarding a new Swedish patent for OnZurf Probe has been approved, strengthening Senzime’s existing patent portfolio. The Onzurf Probe is a new generation of microdialysis probes that enable organ-specific biological monitoring of various organs such and the bowel, liver and kidney after surgery. The technology makes it possible to monitor the organs’ healing process and to provide early warning signs of complications such as ischemia and anastomotic failure.

Resolutions at Senzime AB’s (publ) Annual General Meeting

Senzime AB (publ) held its annual general meeting on May 23, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Retransmitting: Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

Senzime receives research grants from Green Innovation Park

Uppsala, 19 May 2017. Senzime (publ) receives research grant from Green Innovation Park (GIP). This collaborative study is aimed at evaluating the usability of OnZurf Probe to monitor dispersion of various substances in soil. The study will be conducted at Swedish University of Agricultural Sciences (SLU) in Umeå, as a collaboration between Senzime and researchers in the Department of Forest Ecology and Care. The grant of 50,000 SEK allows the company to expand the market opportunities for OnZurf Probe to include ecologic monitoring.

Senzime participated at the International Anesthesia Research Society Annual meeting, IARS

Washington DC May 6-9, 2017

TetraGraph Functionality in Scientific Abstract at IARS, Washington DC

Uppsala, May 5th, 2017.  Senzime AB (publ) today announced that the scientific abstract, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” is to be presented at the International Anesthesia Research Society (IARS) meeting in Washington, DC where 1200 anesthesiologists participate.

Senzime’s Annual Report 2016

Uppsala, April 28, 2017. Senzime AB’s (publ) annual report for fiscal year 2016 is now available on the company’s webbsite www.senzime.com.

Senzime’s Annual Report 2016

Uppsala, April 28, 2017. Senzime AB’s (publ) annual report for fiscal year 2016 is now available on the company’s webbsite www.senzime.com.

Senzimes first day of trading on Nasdaq First North

Uppsala, April 11, 2017. Senzime AB (publ) recently completed a rights issue that raised SEK 24.4 million before issue costs. Senzime has applied for listing on Nasdaq First North which has been approved with first day of trading April 11, 2017. Previously Senzime was listed on AktieTorget.

Senzime’s rights issue oversubscribed

The subscription period for Senzime AB (publ)’s rights issue with pre-emption rights for existing shareholders (the "Rights Issue") expired on 28 March 2017 and the company is pleased to announce that there has been large interest in the subscription of shares. The Rights Issue was oversubscribed to approximately 103 percent under the original offer. Thus, the company will raise approximately SEK 24.4 million before issue costs, estimated at SEK 3.1 million.

Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North

Uppsala, March 14, 2017. The Board of Senzime AB (publ) ("Senzime") has prepared a prospectus regarding the rights issue that was resolved at the extraordinary general meeting in Senzime on March 3, 2017. The Board of Senzime has also applied for listing on Nasdaq First North, and the first day of trading on Nasdaq First North is expected to be April 11, 2017.

Preliminary results to be presented at IARS 2017

Uppsala, March 13, 2017. Senzime AB (publ) is happy to announce that the abstract authored by Dr. J. Ross Renew from the Mayo Clinic and entitled, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” was accepted for publication. The volunteer study compared the TetraGraph and TOF-Watch, and the results will be presented at IARS (International Anesthesia Research Society) 2017 Annual Meeting and International Science Symposium, in Washington DC, May 6-9.

Bulletin from the Extraordinary General Meeting in Senzime AB (publ) – resolution on new issue of shares

The shareholders of Senzime have at the Extraordinary General Meeting on March 3, 2017 resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders. 

Notice of Extraordinary General Meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9.30 (local time) on Friday 3 March 2017 in the premises of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

Year-end Bulletin 2016

“We continue to build a new global leader in the field of patient monitoring”

is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North

Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.

Senzime signs distribution agreements for the TetraGraph

Uppsala, February 9, 2017. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in the UK, Ireland, Australia and New Zealand.